These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37164738)

  • 41. Concomitant Use of Aminosalicylates Is Not Associated With Improved Outcomes in Patients With Ulcerative Colitis Escalated to Vedolizumab.
    Ma C; Kotze PG; Almutairdi A; Jairath V; Panaccione R
    Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2374-2376.e2. PubMed ID: 30528845
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Baseline levels of dynamic CD4
    Allner C; Melde M; Becker E; Fuchs F; Mühl L; Klenske E; Müller L; Morgenstern N; Fietkau K; Hirschmann S; Atreya R; Atreya I; Neurath MF; Zundler S
    BMC Gastroenterol; 2020 Apr; 20(1):103. PubMed ID: 32293299
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical response of vedolizumab at week 6 predicted endoscopic remission at week 24 in ulcerative colitis.
    Saito D; Matsuura M; Ozaki R; Tokunaga S; Minowa S; Mitsui T; Miura M; Sakuraba A; Hayashida M; Miyoshi J; Hisamatsu T
    JGH Open; 2021 Sep; 5(9):1056-1062. PubMed ID: 34584975
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease.
    Singh N; Rabizadeh S; Jossen J; Pittman N; Check M; Hashemi G; Phan BL; Hyams JS; Dubinsky MC
    Inflamm Bowel Dis; 2016 Sep; 22(9):2121-6. PubMed ID: 27542130
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY).
    Peyrin-Biroulet L; Loftus EV; Colombel JF; Danese S; Rogers R; Bornstein JD; Chen J; Schreiber S; Sands BE; Lirio RA
    Gastroenterology; 2021 Oct; 161(4):1156-1167.e3. PubMed ID: 34144047
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
    Danese S; Colombel JF; Lukas M; Gisbert JP; D'Haens G; Hayee B; Panaccione R; Kim HS; Reinisch W; Tyrrell H; Oh YS; Tole S; Chai A; Chamberlain-James K; Tang MT; Schreiber S;
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):118-127. PubMed ID: 34798038
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).
    Eriksson C; Marsal J; Bergemalm D; Vigren L; Björk J; Eberhardson M; Karling P; Söderman C; ; Myrelid P; Cao Y; Sjöberg D; Thörn M; Karlén P; Hertervig E; Strid H; Ludvigsson JF; Almer S; Halfvarson J
    Scand J Gastroenterol; 2017; 52(6-7):722-729. PubMed ID: 28362144
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
    Sands BE; Peyrin-Biroulet L; Loftus EV; Danese S; Colombel JF; Törüner M; Jonaitis L; Abhyankar B; Chen J; Rogers R; Lirio RA; Bornstein JD; Schreiber S;
    N Engl J Med; 2019 Sep; 381(13):1215-1226. PubMed ID: 31553834
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis.
    Ollech JE; Dwadasi S; Rai V; Peleg N; Normatov I; Israel A; Sossenheimer PH; Christensen B; Pekow J; Dalal SR; Sakuraba A; Cohen RD; Rubin DT
    Aliment Pharmacol Ther; 2020 Mar; 51(6):637-643. PubMed ID: 31875986
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort Study.
    Martin A; Nachury M; Peyrin-Biroulet L; Bouhnik Y; Nancey S; Bourrier A; Serrero M; Fumery M; Buisson A; Laharie D; Gilletta C; Filippi J; Allez M; Bouguen G; Roblin X; Altwegg R; Dib N; Pineton de Chambrun G; Savoye G; Carbonnel F; Viennot S; Amiot A;
    J Crohns Colitis; 2020 Jul; 14(7):896-903. PubMed ID: 31930285
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis.
    Jairath V; Chan K; Lasch K; Keeping S; Agboton C; Blake A; Patel H
    Expert Rev Gastroenterol Hepatol; 2021 Jun; 15(6):711-722. PubMed ID: 33599181
    [No Abstract]   [Full Text] [Related]  

  • 52. Vedolizumab for the treatment of ulcerative colitis.
    Shahidi N; Bressler B; Panaccione R
    Expert Opin Biol Ther; 2016; 16(1):129-35. PubMed ID: 26567768
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The biologics of ulcerative colitis.
    Macaluso FS; Renna S; Orlando A; Cottone M
    Expert Opin Biol Ther; 2017 Feb; 17(2):175-184. PubMed ID: 27960557
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of vedolizumab in the treatment of ulcerative colitis.
    Domènech E; Gisbert JP
    Gastroenterol Hepatol; 2016 Dec; 39(10):677-686. PubMed ID: 26948838
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Introduction of Subcutaneous Infliximab CT-P13 and Vedolizumab in Clinical Practice: A Multi-Stakeholder Position Statement Highlighting the Need for Post-Marketing Studies.
    Fierens L; Liefferinckx C; Hoefkens E; Lobatòn T; Dreesen E; Sabino J; Ferrante M;
    J Crohns Colitis; 2022 Aug; 16(7):1059-1069. PubMed ID: 35078228
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A review of the cost-effectiveness of vedolizumab for treating moderate- to severely active ulcerative colitis.
    Tsai HH; Black C
    Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):679-683. PubMed ID: 27726457
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pyoderma gangrenosum in an ulcerative colitis patient during treatment with vedolizumab responded favorably to adsorptive granulocyte and monocyte apheresis.
    Shibuya T; Haga K; Saeki M; Haraikawa M; Tsuchihashi H; Okahara K; Nomura O; Fukushima H; Murakami T; Ishikawa D; Ikeda S; Nagahara A
    J Clin Apher; 2020 Sep; 35(5):488-492. PubMed ID: 32767842
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis.
    Lawson MM; Thomas AG; Akobeng AK
    Cochrane Database Syst Rev; 2006 Jul; (3):CD005112. PubMed ID: 16856078
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative Long-Term Drug Survival of Vedolizumab, Adalimumab, and Infliximab in Biologic-Naïve Patients with Ulcerative Colitis.
    Dalal RS; McClure EL; Marcus J; Allegretti JR
    Dig Dis Sci; 2023 Jan; 68(1):223-232. PubMed ID: 35415826
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vedolizumab: a review of its use in adult patients with moderately to severely active ulcerative colitis or Crohn's disease.
    Garnock-Jones KP
    BioDrugs; 2015 Feb; 29(1):57-67. PubMed ID: 25502899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.